JP2016521539A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521539A5
JP2016521539A5 JP2015558676A JP2015558676A JP2016521539A5 JP 2016521539 A5 JP2016521539 A5 JP 2016521539A5 JP 2015558676 A JP2015558676 A JP 2015558676A JP 2015558676 A JP2015558676 A JP 2015558676A JP 2016521539 A5 JP2016521539 A5 JP 2016521539A5
Authority
JP
Japan
Prior art keywords
virus
particle
antigen
malaria
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521539A (ja
JP6734651B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2014/065166 external-priority patent/WO2014196648A1/en
Publication of JP2016521539A publication Critical patent/JP2016521539A/ja
Publication of JP2016521539A5 publication Critical patent/JP2016521539A5/ja
Application granted granted Critical
Publication of JP6734651B2 publication Critical patent/JP6734651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558676A 2013-06-03 2014-06-02 マラリアワクチン Active JP6734651B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361830436P 2013-06-03 2013-06-03
US61/830,436 2013-06-03
US201361906583P 2013-11-20 2013-11-20
US61/906,583 2013-11-20
PCT/JP2014/065166 WO2014196648A1 (en) 2013-06-03 2014-06-02 Malaria vaccine

Publications (3)

Publication Number Publication Date
JP2016521539A JP2016521539A (ja) 2016-07-25
JP2016521539A5 true JP2016521539A5 (https=) 2017-07-06
JP6734651B2 JP6734651B2 (ja) 2020-08-05

Family

ID=52005658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558676A Active JP6734651B2 (ja) 2013-06-03 2014-06-02 マラリアワクチン

Country Status (16)

Country Link
US (3) US9512190B2 (https=)
EP (1) EP3004348B1 (https=)
JP (1) JP6734651B2 (https=)
KR (2) KR102494564B1 (https=)
CN (1) CN105431535A (https=)
AP (1) AP2015008926A0 (https=)
AU (1) AU2014275772B2 (https=)
BR (1) BR112015030229B1 (https=)
CA (1) CA2913832C (https=)
IL (1) IL242656B (https=)
MX (1) MX386234B (https=)
RU (1) RU2702163C2 (https=)
SG (2) SG10201709917VA (https=)
TW (1) TWI687442B (https=)
WO (1) WO2014196648A1 (https=)
ZA (1) ZA201508642B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102181258B1 (ko) 2012-02-16 2020-11-20 브이엘피 테라퓨틱스 엘엘씨 바이러스 유사 입자 조성물
TWI676636B (zh) 2013-07-12 2019-11-11 Vlp醫療股份有限公司 包含pd-1抗原或pd-1配體抗原的類病毒粒子
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
KR102532832B1 (ko) 2014-09-11 2023-05-16 브이엘피 테라퓨틱스 인코포레이티드 플라비바이러스 바이러스 유사 입자
US10166281B2 (en) * 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
US9968665B2 (en) 2015-09-16 2018-05-15 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
TWI891771B (zh) 2020-04-17 2025-08-01 美商Vlp醫療股份有限公司 冠狀病毒疫苗
AU2021264216A1 (en) 2020-04-30 2022-11-10 Vlp Therapeutics, Inc. Cytokine immunotherapy
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2023092143A1 (en) * 2021-11-22 2023-05-25 Novavax AB Methods and compositions for treating and preventing malaria
WO2025064770A2 (en) * 2023-09-20 2025-03-27 La Jolla Institute of Immunology Alphavirus t cell epitopes, megapools and uses thereof
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Cyn-Kバイオ株式会社 肥満の処置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
AU2003295470A1 (en) * 2002-11-13 2004-06-03 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
EA016648B1 (ru) * 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20100120092A1 (en) * 2006-08-30 2010-05-13 Hepgenics Pty Ltd. Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
EP2370455B1 (en) * 2008-11-26 2019-07-03 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus like particle compositions and methods of use
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
EP2477650B8 (en) * 2009-09-18 2019-10-09 FRAUNHOFER USA Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) * 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) * 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
US9487563B2 (en) * 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
KR102181258B1 (ko) * 2012-02-16 2020-11-20 브이엘피 테라퓨틱스 엘엘씨 바이러스 유사 입자 조성물
US9969986B2 (en) 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3

Similar Documents

Publication Publication Date Title
JP2016521539A5 (https=)
JP2015508648A5 (https=)
EP3177720B1 (en) Virus like particle comprising modified envelope protein e3
RU2014133527A (ru) Композиция вирусоподобных частиц
US10464986B2 (en) Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
AU2014275772B2 (en) Malaria vaccine
US10385101B2 (en) Virus like particle comprising modified envelope protein E3
JP2016501535A5 (https=)
JP2017513502A5 (https=)
RU2017132190A (ru) Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
CN102112601B (zh) 新的融合蛋白及其用于制备针对丙型肝炎的疫苗的用途
JP2009522368A5 (https=)
CN107074968B (zh) 疫苗
JP2024533123A5 (https=)
TH112180A (th) โปรตีนผสมชนิดใหม่ ๆ และการใช้โปรตีนเหล่านี้เพื่อการเตรียมวัคซีนต้านไวรัสตับอักเสบ ซี
TH1801007049A (th) วัคซีน
CN101502657A (zh) 噬菌体与EB病毒的gp350蛋白融合载体疫苗的构建方法
TH159031A (th) ไวรัสโรคหัดชนิดรีคอมบิแนนท์ที่แสดงออกถึงโพลิเพปไทด์ของไวรัสชิคุนกุนยา และการประยุกต์ใช้